The Usage of Oblongifolin C, a Natural Compound from Garcinia yunnanensis Hu, on Treating High Metastatic Cancer
Yhe present invention to provide a compound, Oblongifolin C, a natural compund isolated from Garcinia yunnanensis Hu, for its effects of anti-migration and anti-invasion against esophageal cancer and its use as anticancer drug against esophageal cancer.
In this invention, we found that Oblongifolin C, a natural compound from Garcinia yunnanensis Hu, can inhibit the migration and invasion of esophageal cancer.
Oblongifolin C can be developed as anticancer drug against esophageal cancer.
We have screened various components using different cancer cells, and found that several polyprenylated acylphloroglucinol (PPAP) compounds had potent cytotoxic effects on human colorectal cancer cell lines without affecting the normal human colon fibroblasts. In this invention, we found that Oblongifolin C can significantly inhibit esophageal cancer cell (ESCC) ECA109 migration and invasion. Thus, Oblongifolin C can be developed as anticancer drug against esophageal cancer.
Inventor: DRANOFF, Glenn | VANNEMAN, Matthew | FREEMAN, Gordon
Priority Number: WO2010080124A9
IPC Current: A61K003816 | A61P003500
Assignee Applicant: Dana-Farber Cancer Institute Inc.
Title: NKG2D-FC FOR IMMUNOTHERAPY | NKG2D-FC POUR IMMUNOTHÉRAPIE
Usefulness: NKG2D-FC FOR IMMUNOTHERAPY | NKG2D-FC POUR IMMUNOTHÉRAPIE
Summary: The method is useful for treating cancer including melanoma, lung cancer, plasma cell cancer, leukemia, lymphoma, ovarian cancer, colon cancer, pancreatic cancer and prostate cancer in subjects (claimed) e.g. humans.
Novelty: Treating cancer e.g. melanoma, lung cancer and leukemia in subject e.g. human having NKGD ligand expressing cancer, involves administering composition comprising NKG2D-Fc chimera, and carrier to subject
Disease Diagnostic/Treatment
Cancer/Tumor
2013.01.10
US 61/750,870
Filed
A61/BZ/Oblo/US0P
Hong Kong
